SEER:NASDAQSeer, Inc. Analysis
Data as of 2026-04-30 - not real-time
$1.88
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Seer, Inc. is trading near its 20‑day SMA, which sits just above the 50‑day SMA, while the 14‑day RSI hovers around the midpoint, indicating a neutral price stance. The MACD histogram has turned marginally negative and the signal line is labeled bearish, suggesting short‑term downside pressure despite the modest bullish bias from the moving averages. Volatility remains elevated at over 45% on a 30‑day basis and beta is below one, reflecting a stock that is less volatile than the market but still subject to sharp swings. Fundamentally, the company reports negative earnings, a negative forward PE and operating margins in the low‑single digits, yet its price‑to‑book ratio is well under 1 and it holds a sizable cash cushion that dwarfs its modest debt load. Recent material news reveals an activist‑led, non‑binding acquisition proposal offering $2.35 per share—a roughly 39% premium to the current price—introducing a potential catalyst that could reprice the stock if negotiations progress.
Overall, the blend of a cash‑rich balance sheet, an undervalued book value, and a premium‑bearing takeover bid creates a nuanced picture: the stock is financially resilient but operationally challenged, and the near‑term trajectory will hinge on the outcome of the acquisition discussions and the market’s response to the bearish technical signals.
Overall, the blend of a cash‑rich balance sheet, an undervalued book value, and a premium‑bearing takeover bid creates a nuanced picture: the stock is financially resilient but operationally challenged, and the near‑term trajectory will hinge on the outcome of the acquisition discussions and the market’s response to the bearish technical signals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- bearish MACD signal
- decreasing volume trend
- pending acquisition proposal
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- potential 39% acquisition premium
- strong cash position relative to debt
- price-to-book ratio well below 1
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- ongoing R&D in proteomics market
- high sector and regulatory risk
- current negative earnings and margins
Key Metrics & Analysis
Financial Health
Revenue Growth5.00%
P/E Ratio-1.8
ROE-25.08%
ROA-14.71%
Debt/Equity9.12
P/B Ratio0.4
Op. Cash Flow$-44448000
Free Cash Flow$-27648000
Industry P/E25.2
Technical Analysis
TrendNeutral
RSI50.6
Support$1.66
Resistance$2.05
MA 20$1.87
MA 50$1.84
MA 200$1.99
MACDBearish
VolumeDecreasing
Fear & Greed Index88.27
Valuation
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.81
Volatility45.60%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.